Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071067 | 0.76 | SMN1; SMN2 (0.46) | HPGDLMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL4588132 | 0.76 | GSK3B (0.41) | LMNAALDH1A1MAPTGAARAB9A | |
| SCHEMBL7984182 | 0.74 | GAA (0.52) | HPGDLMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL3166632 | 0.74 | POLB (0.44) | LMNAALDH1A1POLBMAPTHTT | |
| SCHEMBL1515208 | 0.72 | MAPT (0.41) | LMNAALDH1A1POLBMAPTGAA | |
| SCHEMBL83922 | 0.72 | HPGD (0.86) | HPGDLMNAALDH1A1POLBCYP1A2 | |
| SCHEMBL1362962 | 0.72 | CYP3A4 (0.40) | HPGDLMNAALDH1A1POLBGAA | |
| SCHEMBL14340617 | 0.71 | MAPT (0.47) | HPGDLMNAALDH1A1MAPTGAA | |
| SCHEMBL75884 | 0.71 | SMN1; SMN2 (0.54) | LMNAALDH1A1CYP1A2MAPTGAA | |
| SCHEMBL1649522 | 0.70 | EPHX1 (0.59) | HPGDLMNAALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | claimed |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2004-10-28 | — | — | US | claimed |
| EP-1440976-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-28 | — | — | EP | claimed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | claimed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | claimed |
| EP-0876347-B1 | QUINOLINE DERIVATIVES | GLAXOSMITHKLINE SPA (IT) | 2005-03-02 | — | — | EP | disclosed |
| EP-1440976-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-28 | — | — | EP | disclosed |
| US-6277862-B1 | METABOLICALLY STABLE NON-PEPTIDE NEUROKININ (NK-2 AND NK-3) ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 2001-08-21 | — | — | US | disclosed |
| EP-0876347-A1 | QUINOLINE DERIVATIVES | Smithkline Beecham S.p.A. (IT) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997021680-A9 | QUINOLINE DERIVATIVES | — | 1997-09-12 | — | — | WO | disclosed |
| WO-1997021680-A1 | QUINOLINE DERIVATIVES | SMITHKLINE BEECHAM S.P.A. (IT) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | HPGD 3959/4885LMNA 1992/4885ALDH1A1 2929/4885 |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | HPGD 3669/4885LMNA 2240/4885ALDH1A1 2196/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | HPGD 3365/4885LMNA 2510/4885ALDH1A1 1704/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | HPGD 3669/4885LMNA 2240/4885ALDH1A1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.